Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

Delayed Data
As of Jul 27
 +0.02 / +0.09%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company, which uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. It is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus. These inhibitors include members of the direct acting antiviral inhibitor classes - protease, NS5A and nucleotide polymerase - as well as a host-targeted antiviral inhibitor class targeted against cyclophilin. Additionally, the company has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community methicillin-resistant Staphylococcus aureus infections. Enanta Pharmaceuticals was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Contact Information

Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown Massachusetts 02472
P:(617) 607-0800
Investor Relations:
(617) 607-0710



Other institutional42.95%
Individual stakeholders35.83%
Mutual fund holders34.03%

Top Executives

Jay R. LulyPresident, Chief Executive Officer & Director
Paul J. MellettChief Financial Officer & Senior VP-Administration
Yat-Sun OrChief Scientific Officer & Senior VP-Research
Nathalie AddaChief Medical Officer & Senior Vice President
Nathaniel S. GardinerSecretary, Senior Vice President & General Counsel